Hyqvia?

What is Hyqvia?

Hyqvia is a human immunoglobulin (Ig) therapy used for the treatment of primary immunodeficiency disorders in adults and children. It is a subcutaneous injection of intravenous immunoglobulin (IVIG) that combines the benefits of IVIG with the comfort and convenience of a subcutaneous administration.[1] Hyqvia was developed by CSL Behring.

How does Hyqvia compare to traditional IVIG?

Hyqvia is a liquid formulation of IgG1 antibodies, which are the primary components of IVIG. When administered subcutaneously, it has shown comparable efficacy to IVIG[2]. The subcutaneous route of administration can offer advantages such as reduced venous access complications, fewer infusion-site reactions, and greater patient flexibility.

Side effects and concerns

As with all immunoglobulin therapies, patients may experience infusion-site reactions, headache, fatigue, fever, and other side effects. Patients should discuss any potential risks and benefits with their healthcare provider.

Patent and exclusivity

According to DrugPatentWatch.com [3], the patent for Hyqvia expired in 2021. However, regulatory and marketing exclusivities may remain in effect.

Availability and pricing

Hyqvia is available in the United States through CSL Behring. The cost of Hyqvia may vary depending on the patient's insurance coverage and location. For more information, patients and healthcare providers should consult the manufacturer's website or contact their local distributor.

References

[1] CSL Behring. (n.d.). Hyqvia (Immune Globulin Subcutaneous, 10% solution). Retrieved from https://www.cslbehring.com/our-products/human-immunoglobulin-products/hyqvia/

[2] Ballow, M., et al. (2011). Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases. Journal of Clinical Immunology, 31(3), 442-451. doi: 10.1007/s10875-011-9563-7

[3] DrugPatentWatch.com. (n.d.). Hyqvia (immune globulin subcutaneous (human)). Retrieved from https://www.drugpatentwatch.com/drug/hyqvia